for the Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators Background-Loss of negative feedback inhibition of renin release during chronic treatment with an angiotensinconverting enzyme (ACE) inhibitor leads to a compensatory rise in renin secretion and downstream components of the renin-angiotensin-aldosterone (RAAS) cascade. This may overcome ACE inhibition but should be blocked by a direct renin inhibitor. We studied the effects of adding the direct renin inhibitor aliskiren to an ACE inhibitor in patients with heart failure. Methods and Results-Patients with New York Heart Association class II to IV heart failure, current or past history of hypertension, and plasma brain natriuretic peptide (BNP) concentration Ͼ100 pg/mL who had been treated with an ACE inhibitor (or angiotensin receptor blocker) and ␤-blocker were randomized to 3 months of treatment with placebo (nϭ146) or aliskiren 150 mg/d (nϭ156). The primary efficacy outcome was the between-treatment difference in N-terminal pro-BNP (NT-proBNP). Patients' mean age was 68 years, mean ejection fraction was 31%, and meanϮSD systolic blood pressure was 129Ϯ17.4 mm Hg. Sixty-two percent of the patients were in New York Heart Association functional class II, and 33% were taking an aldosterone antagonist. Plasma NT-proBNP rose by 762Ϯ6123 pg/mL with placebo and fell by 244Ϯ2025 pg/mL with aliskiren (Pϭ0.0106). BNP and urinary (but not plasma) aldosterone were also reduced by aliskiren. Clinically important differences in blood pressure and biochemistry were not seen between aliskiren and placebo. Conclusions-Addition of aliskiren to an ACE inhibitor (or angiotensin receptor blocker) and ␤-blocker had favorable neurohumoral effects in heart failure and appeared to be well tolerated. (Circ Heart Fail. 2008;1:17-24.) 
T he value of inhibiting the renin-angiotensin-aldosterone system (RAAS) in heart failure was first demonstrated with the angiotensin-converting enzyme (ACE) inhibitor enalapril in 1987. 1 Since then, there have been 2 major aims of therapeutic research with inhibitors of the RAAS in heart failure. 2 The first has been to determine whether alternative agents offered superior efficacy, tolerability, or both as a result of their distinctive pharmacological actions. In the only head-to-head comparison, the angiotensin receptor blocker (ARB) losartan was not superior to the ACE inhibitor captopril. 3 The second aim, based on the pathophysiological observations of aldosterone "escape" in patients treated with an ACE inhibitor and of non-ACE generation of angiotensin II, was to determine whether the combination of RAAS inhibitors could improve clinical outcomes further than with ACE inhibitor monotherapy. This has been shown to be the case for both an aldosterone antagonist 4 and ARBs. 5, 6 
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Direct renin inhibitors (DRIs) offer another pharmacologically distinct means of suppressing the RAAS, with the theoretical advantages of blocking an enzyme with only one known substrate (angiotensinogen), inhibiting the ratelimiting step in the RAAS cascade, and reducing synthesis of all subsequent components of the cascade. 7 As with ARBs, DRIs may offer an alternative to an ACE inhibitor or could be used in combination with an ACE inhibitor (or ARB). 2 The rationale for the latter approach is that ACE inhibitors (and ARBs) induce a compensatory rise in renin and downstream RAAS components that may eventually overcome their RAAS-blocking effect. A DRI should block this compensatory increase in RAAS activity. Conversely, the addition of an ACE inhibitor (or ARB) to a DRI may be valuable in view of the possibility of nonrenin production of angiotensin I through enzymes such as cathepsin D and tonin. 8 -10 We studied the effects of adding the DRI aliskiren to an ACE inhibitor or ARB in patients with chronic symptomatic heart failure.
Methods

Patients
Men and women Ն18 years of age were eligible if they fulfilled each of the following criteria and provided written informed consent: (1) stable New York Heart Association class II to IV heart failure for at least 1 month; (2) past or current diagnosis of essential hypertension;
(3) stable dose of an ACE inhibitor (or ARB) and a ␤-blocker (unless there was a contraindication or intolerance to such therapy); and (4) plasma brain natriuretic peptide (BNP) Ͼ100 pg/mL (28.9 pmol/L). There was no left ventricular ejection fraction (LVEF) inclusion criterion. The key exclusion criteria included treatment with both an ACE inhibitor and an ARB (combination of either with an aldosterone antagonist was permitted); heart failure related to obstructive valve disease or hypertrophic, restrictive, or infective cardiomyopathy, pregnancy, or lung disease; systolic blood pressure Ͻ90 mm Hg; serum potassium Ն5.1 mmol/L; creatinine Ͼ2.0 mg/dL (177 mol/L) or history of dialysis or nephrotic syndrome; myocardial infarction, cerebrovascular accident or transient ischemic attack, or coronary revascularization within 6 months; cardiac resynchronization device or implantable cardioverter defibrillator; and prior malignancy or other disease likely to greatly limit life expectancy, adherence to the protocol, or absorption of study drug.
Procedures
Patients were enrolled at 75 sites in 9 countries (Figure) . The study consisted of 2 phases: a 2-week single-blind placebo run-in period (to assess eligibility, particularly BNP concentration, and patient adherence to study drug), and a 12-week randomized, double-blind, parallel-group phase in which patients received either placebo or aliskiren 150 mg once daily in an equal ratio ( Figure) . The randomization list was generated by Novartis Drug Supply Management (Basel, Switzerland) with a validated system that automated the random assignment of treatment groups to randomization numbers. The randomization scheme was reviewed by a biostatistics quality assurance group at Novartis and locked by that group after approval. Placebo and drug tablets and capsules were matched in size, shape, and color to maintain blinding.
Randomization was done by a telephonic interactive voice response system with stratification by center and locally determined LVEF at baseline (stratum 1: Ͼ 40%; stratum 2: Յ40%) to ensure a balanced LVEF distribution within each treatment group. Within a stratum (LVEF within center), a block size of 4 was used. Within centers, the number of patients randomized to the 2 treatment groups never differed by more than 3 patients. For the 2 centers where the difference between groups was 3 patients, the randomization was 2 versus 5 and 3 versus 0.
Patients were evaluated at 2, 4, 8, and 12 weeks after randomization. Blood chemistry was checked at each of these time points. The protocol specified that any patient admitted to a hospital because of worsening heart failure or with serum potassium Ͼ5.5 mmol/L or serum creatinine Ͼ3 mg/dL (265 mol/L), confirmed by the central laboratory (CRL Medinet Inc, Lenexa, Kan, and CRL Medinet BV, Breda, the Netherlands), should be withdrawn from the study.
The primary objective of the present study was to assess the tolerability and safety of aliskiren, specifically the incidence of renal dysfunction (any relevant Medical Dictionary for Regulatory Activities adverse event term or increase in creatinine to Ͼ3.0 mg/dL [267 mol/L]), symptomatic hypotension (any relevant Medical Dictionary for Regulatory Activities adverse event term), and hyperkalemia (potassium Ͼ5.5 mmol/L, confirmed by the central laboratory or Medical Dictionary for Regulatory Activities adverse event term for hyperkalemia), in hierarchical order. Efficacy assessments were also prespecified. The aims were to evaluate the effect of aliskiren, compared with placebo, on N-terminal pro-BNP (NT-proBNP), BNP, aldosterone, signs and symptoms of heart failure (and New York Heart Association class), echocardiographic measures of cardiac size and ventricular function, blood pressure, heart rate variability, quality of life (Kansas City Cardiomyopathy Questionnaire), neurohumoral and inflammatory biomarkers (including urinary biomarkers), and glycemic measures (in the order specified).
Echocardiograms were obtained at the sites after centralized site training at investigator meetings. All echocardiographic studies were obtained digitally or on videotape and transferred to the core echocardiography laboratory at the Brigham and Women's Hospital (Boston, Mass) for analysis. Echocardiograms were digitized and analyzed by trained echocardiographers blinded to treatment assignment. Endocardial borders were traced manually in multiple views, left ventricular volumes were measured by the Simpson's rule method, 11 and ejection fraction was calculated in the standard fashion. Mitral regurgitation was assessed semiquantitatively by calculating the ratio of mitral regurgitant jet area to left atrial area in apical 2-and 4-chamber views. Doppler parameters, including peak early (E) transmitral flow velocity, peak atrial (A) transmitral flow velocity, and tissue Doppler EЈ and SЈ, representing annular relaxation and contraction velocity, respectively, were measured. The ratio of transmitral E wave to tissue Doppler EЈ was calculated, as was Tei's index. 12
Statistical Analysis
Although this was primarily a safety study, we calculated a sample size on the basis of the ability to detect a difference between treatment groups in the change from baseline to the end of the study in NT-proBNP, which was also the first of the prespecified secondary efficacy assessments. Inspection of existing data on BNP suggested that assumption of a normal distribution was most appropriate for log-transformed data. Assuming a standard deviation of 0.65 for the logarithmized NT-proBNP ratio of end of study to baseline, an ␣-level for statistical significance of 0.05 (2 sided), a dropout rate of 10%, and 250 patients, the study had 72% power to detect a 20% reduction and 89% power to detect a 25% reduction in NT-proBNP.
The change from baseline to end of study was analyzed with a 2-way ANCOVA model with adjustment for treatment, region of the world, and core laboratory LVEF (Ͻ40% and Ն40%). For parameters for which the data were highly skewed and did not fit a normal distribution (including NT-proBNP, BNP, and aldosterone), the analysis was performed on the change from end of study to baseline with log-transformed data. The least-squares means of the treatment effects were back-transformed (antilog) and, given the properties of logarithms, are an estimate of the ratio of the end point to baseline. This is comparable to the ratio of end point to baseline of the geometric means. The treatment comparisons presented are the ratio of the 2 treatment effects.
Prespecified hypothesis tests with the Fisher exact test were performed on the primary safety parameters, as well as additional tests that compared the incidence of adverse events. Treatment comparisons were investigated with a Cochran-Mantel-Haenszel 2 test, with adjustment for LVEF (Ͼ40% or Յ40%).
All statistical analyses were performed with SAS version 8.2 (or higher) by the sponsor (J.F.) and checked by an independent statistician at Glasgow University (J.L.). Because the efficacy assessments were exploratory, no adjustment was made for multiple statistical comparisons.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
The baseline characteristics of the 302 patients randomized (Figure) are shown in Table 1 . The majority were male. All had a history of hypertension according to the inclusion criteria, but baseline seated blood pressure was 129Ϯ17.4 mm Hg systolic and 77Ϯ9.5 mm Hg diastolic. Although a low LVEF was not an inclusion criterion, 79% of 
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patients had an LVEF Յ40%, and the meanϮSD LVEF was 31Ϯ5.5%. Thirty-five percent of patients had a history of diabetes mellitus. Ninety percent of patients had a plasma BNP concentration Ͼ150 pg/mL (43 pmol/L), and the meanϮSD value was 291Ϯ265 pg/mL ( Table 2 ). Most patients were in New York Heart Association functional class II (61%) or III (38%) and were treated with neurohumoral blockers. Ninety-four percent were treated with an ACE inhibitor (or ARB) and ␤-blocker and 32% with an aldosterone antagonist as well. Of the 302 patients randomized, 277 (92%) completed the double-blind treatment phase. Plasma NT-proBNP rose by a meanϮSD of 762Ϯ6123 pg/mL over the 12 weeks of treatment in the placebo group and fell by a meanϮSD of 244Ϯ2025 pg/mL with aliskiren treatment (between-treatment difference in change from baseline Pϭ0.0106; Table 2 ). BNP decreased by a meanϮSD of 12.2Ϯ243 pg/mL in the placebo group and by 61.0Ϯ257 pg/mL in the aliskiren group (Pϭ0.0160). Plasma aldosterone did not differ between groups, but urinary aldosterone excretion decreased more in the aliskiren group; the decrease with aliskiren was 9.24Ϯ42.9 nmol/d, and the decrease with placebo was 6.96Ϯ38.5 nmol/d (Pϭ0.0150; Table 2 ). Plasma renin activity decreased more with aliskiren (decrease of 5.71Ϯ11.27 ng · mL Ϫ1 · h Ϫ1 with aliskiren compared with a decrease of 0.97Ϯ9.96 ng · mL Ϫ1 · h Ϫ1 with placebo; PϽ0.0001; Table 2 ).
There was no difference between treatments for change in symptoms or signs between baseline and the end of the study. There were no differences in echocardiographic measurements of wall thickness, chamber volumes, or LVEF. We observed significant reductions in the degree of mitral regurgitation, transmitral E velocity, and ratio of mitral velocity to early diastolic velocity of the mitral annulus in patients treated with aliskiren, although no adjustment was made for the multiple comparisons that were performed ( Table 3 ).
The meanϮSD decrease in seated systolic blood pressure was 1.7Ϯ13.2 mm Hg in the placebo group and 4.1Ϯ14.5 mm Hg in the aliskiren group (Pϭ0.2257). The corresponding decreases in diastolic blood pressure were 0.2Ϯ8.6 mm Hg in the placebo group and 2.9Ϯ9.0 mm Hg in the aliskiren group (Pϭ0.0599). The mean increase in heart rate was 0.2Ϯ10.3 bpm in the placebo group and 1.1Ϯ13.6 bpm in the aliskiren group (Pϭ0.6774). Mean standing systolic blood pressure decreased by 1.7Ϯ13.1 mm Hg in the placebo group and by 3.5Ϯ16.1 mm Hg in the aliskiren group (Pϭ0.497). The corresponding changes in diastolic blood pressure were a 0.7Ϯ8.3-mm Hg increase with placebo and a 3.5Ϯ10.7-mm Hg decrease with aliskiren (Pϭ0.0045). Standing heart rate decreased by 0.3Ϯ11.4 bpm in the placebo group and increased by 0.7Ϯ13.8 bpm in the aliskiren group (Pϭ0.466). There were no differences between treatments in any of the other prespecified comparisons, including autonomic measurements, the Kansas City Cardiomyopathy questionnaire, inflammatory and other plasma and urinary biomarkers (including urinary protein excretion), or measurements of glucose/insulin metabolism. Eleven (7.5%) placebo-treated and 14 (9.0%) aliskirentreated patients discontinued use of the study drug prematurely. Of these, 2 placebo-treated and 1 aliskiren-treated patient died, and 4 placebo-treated and 7 aliskiren-treated patients discontinued use of the drug because of an adverse event. Discontinuations related to the primary end point (renal dysfunction, symptomatic hypotension, or hyperkalemia) and worsening heart failure occurred in 4 aliskiren- 
treated patients (2 hypotension, 1 hyperkalemia, and 1 worsening heart failure) and 3 placebo-treated patients (all due to worsening heart failure). One placebo-treated patient (and no aliskiren-treated patients) discontinued the study drug because of an abnormal laboratory value. The remaining 4 placebo-treated and 6 aliskiren-treated patients discontinued the study drug because of a protocol violation, withdrawal of consent, or administrative problems or because they were lost to follow-up (1 placebo-treated patient). The primary safety assessments are shown in Table 4 , along with the most commonly reported adverse events. Important biochemical changes are described in Table 5 . The following cardiovascular serious adverse events occurred: sudden death (1 placebo, 0 aliskiren), sudden cardiac death (0 placebo, 1 aliskiren), cardiac arrest (0 placebo, 1 aliskiren), ventricular tachycardia (0 placebo, 1 aliskiren), cerebrovascular accident or transient ischemic attack (0 placebo, 2 aliskiren), heart failure (including cardiac failure, left ventricular failure, pulmonary edema, and paroxysmal nocturnal dyspnea; 2 placebo, 3 aliskiren), unstable angina (0 placebo, 1 aliskiren), atrial fibrillation (0 placebo, 1 aliskiren), tachyarrhythmia (0 placebo, 1 aliskiren), and pulmonary embolism (1 placebo, 0 aliskiren). One aliskiren-treated patient accounted for 3 events-ie, that patient had unstable angina, ventricular tachycardia, and a cardiac arrest.
Discussion
The potential therapeutic value of DRIs has been recognized since 1957, but problems with bioavailability, potency, duration of action, and cost of production hindered their development. 7 Aliskiren, the first of a new class of nonpeptide, orally active, transition-state DRIs, is a potent and specific agent with a plasma half-life of Ϸ24 hours that has recently been approved as a treatment for hypertension in a dose of up to 300 mg. 7, 10, 13, 14 We added 150 mg of aliskiren to the treatment regimen of patients with chronic symptomatic heart failure treated with a stable dose of an ACE inhibitor (or ARB) and a ␤-blocker for at least 1 month. The present study design is important because it tested the effect of a DRI in patients who had experienced the compensatory rise in plasma renin (and other downstream RAAS components) caused by ACE inhibitor-induced (or ARB-induced) loss of negative feedback inhibition of renin secretion. This compensatory response may partially overcome the RAAS-blocking effect of ACE inhibitors. A DRI has not been used in this way previously. In this setting, aliskiren was well tolerated and had favorable neurohumoral effects, reducing the plasma concentration of both natriuretic peptides. Such changes have been associated with improved clinical outcomes in therapeutic trials and observational studies, although no outcome data are available with aliskiren in heart failure.
The decrease in BNP with aliskiren (by 61 pg/mL from a baseline of 301 pg/mL, compared with a rise of 12 pg/mL from a baseline of 273 pg/mL with placebo) was somewhat larger than observed with the addition of ARBs in prior heart failure trials. [15] [16] [17] For example, in the Valsartan Heart Failure Trial (Val-HeFT), BNP decreased from a baseline concentration of 181Ϯ230 pg/mL by 34 pg/mL in the valsartan group at 4 months (compared with an increase of 2 pg/mL in the placebo group). 15 In the African-American Heart Failure Trial (A-HeFT), the combination of hydralazine and isosorbide dinitrate reduced BNP by 39 pg/mL (from a baseline of 283 pg/mL), compared with a decrease of 8 pg/mL in the placebo group. 16 Reductions in BNP have consistently been associated with improved outcome in heart failure. 18 -20 For example, in Val-HeFT, an increment of 10 pg/mL in BNP was associated with a 1.2% increase in risk of death (and an identical increase in the risk of hospitalization for heart failure). 18 In addition, aliskiren reduced urinary aldosterone excretion, although it did not reduce plasma aldosterone concen- Values are provided as number (percentage). There were no statistically significant differences in any assessment. To convert urea to urea-nitrogen (mg/dL), multiply by 2.8; to convert creatinine to mg/dL, divide by 88. 8. tration. Prior experience with "add-on" therapy and plasma aldosterone is less clear-cut. In Val-HeFT, aldosterone fell by 35 pg/mL from a baseline of 144Ϯ143 pg/mL after 4 months of treatment with valsartan (compared with an increase of 10 pg/mL with placebo). 21 In the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study, aldosterone decreased by 20 to 25 pg/mL from a baseline of 114 mg/mL after 17 weeks of treatment with candesartan and enalapril, but this reduction was similar to that observed with 16 mg of candesartan alone (there was no change with enalapril). 22 Measurement of 24-hour urinary aldosterone excretion, however, better quantifies aldosterone secretion than does a single plasma measurement. Reduction in aldosterone secretion can be regarded as a favorable neurohumoral effect of aliskiren, in light of the postulated detrimental pathophysiological role of aldosterone and the beneficial clinical effects of aldosterone antagonists in heart failure. 2 As expected, aliskiren also reduced plasma renin activity (and increased plasma renin concentration). Patients in the present study were treated with a ␤-blocker, which inhibits renin secretion. 23 It was of interest, therefore, that the size of the effect of aliskiren on plasma renin activity was as large in the present trial as in prior studies in which patients were not treated with ␤-blockers. It is also notable that plasma renin activity is itself predictive of mortality and morbidity in patients with heart failure. 18 Aliskiren had no effect on left ventricular wall thickness and volumes or LVEF, probably because of the short duration of treatment and relatively small sample size, although a larger, longer-term study is needed to prove or disprove this hypothesis. Aliskiren did, however, reduce the amount of mitral regurgitation and the ratio of mitral velocity to early diastolic velocity of the mitral annulus, a Doppler measure of left ventricular filling pressure (although the latter analysis was added retrospectively). 24 These findings are in keeping with acute hemodynamic studies with the intravenous renin inhibitors enalkiren and remikiren that showed that those agents reduced pulmonary capillary wedge pressure. 25, 26 They are also consistent with the reduction we observed in BNP and NT-proBNP concentration, although these peptides are thought to give a more integrated measure of "left ventricular stress," and in the present study, the effects were seen with chronic rather than acute therapy; ie, they were sustained over 3 months. 27 Multiple echocardiographic parameters were assessed, and no statistical correction was made for the multiple end points.
There are, however, still some uncertainties about the actions of renin inhibitors. Recently, a receptor that binds renin and prorenin has been identified. 28, 29 Binding of renin to this receptor increases its enzymatic activity, and inert prorenin is converted to active renin when bound. Binding of either peptide to this receptor is also thought to activate intracellular mitogen activated protein kinases and increase synthesis of transforming growth factor-␤, independent of angiotensin formation (possibly stimulating fibrosis). 30 It is uncertain whether DRI-induced increases in renin concentration activate this receptor, whether this receptor is downregulated when renin concentration is increased, and whether aliskiren binds to or blocks this receptor. 30, 31 The addition of aliskiren 150 mg/d to standard therapy for heart failure that includes an ACE inhibitor (or ARB), a ␤-blocker, and an aldosterone antagonist, if indicated, appeared to be well tolerated, with only slightly (but not statistically significantly) higher rates of hypotension and hyperkalemia. There was no notable increase in renal dysfunction, although patients in the present study had been carefully selected, and patients with hypotension, hyperkalemia, or a significantly elevated creatinine at baseline were excluded from this trial (nevertheless, a high proportion had a baseline estimated glomerular filtration rate Ͻ60 mL · min Ϫ1 · 1.73 m Ϫ2 , and one third were taking an aldosterone antagonist). Of possible relevance here is the suggestion that DRIs increase renal blood flow more than other inhibitors of the RAAS.
In summary, these findings in patients with stable New York Heart Association class II and III heart failure and elevated BNP support further trials to test the safety and efficacy of aliskiren in patients with heart failure, either as an alternative to an ACE inhibitor or in combination with other blockers of the RAAS. 31 
